Reconciliation of GAAP to Non-GAAP Financial Measures(in thousands, except per share data – unaudited) Three Months Ended December 31, Twelve Months Ended December 31, 2024 2023 2024 2023 Net (loss) income $ (11,790) $ 103,380 $ 312,442 $ 326,661 Stock and incentive plan compensation 22,164 14,172 76,393 50,507 Amortization of acquired intangible assets 11,846 11,308 43,807 46,440 Campus consolidation costs 35 679 72 3,864 Contingent consideration fair value adjustments (1,294) 200 (2,699) (9,275)Non-recurring refinancing related fees — 5 — 221 Non-recurring fees 6,723 — 6,723 (54,523)Gain on sale of assets (2,161) — (8,415) — Strategic collaboration and license costs (8) — 66,213 — Investment in equity securities - unrealized loss 119,056 — 43,564 — Acquisition-related costs 207 169 1,553 676 Impairment of long-lived assets — — — 138,050 ARO Acceleration and other related costs — 1,187 — 2,232 Other 447 531 2,720 2,725 Income tax effect of non-GAAP adjustments(a) (29,794) (8,950) (57,701) (70,043)Adjusted net income $ 115,431 $ 122,681 $ 484,672 $ 437,535 Adjusted net income, as a percentage of revenues 29.5% 34.7% 31.6% 33.7% Three Months Ended December 31, Twelve Months Ended December 31, 2024 2023 2024 2023 Net (loss) income per share - diluted $ (0.17) $ 1.47 $ 4.36 $ 4.65 Stock and incentive plan compensation 0.31 0.20 1.07 0.72 Amortization of acquired intangible assets 0.16 0.16 0.61 0.66 Campus consolidation costs — 0.01 — 0.06 Contingent consideration fair value adjustments (0.02) — (0.04) (0.13)Non-recurring refinancing related fees — — — — Non-recurring fees 0.09 — 0.09 (0.78)Gain on sale of assets (0.03) — (0.12) — Strategic collaboration and license costs — — 0.92 — Investment in equity securities - unrealized loss 1.65 — 0.61 — Acquisition-related costs — — 0.02 0.01 Impairment of long-lived assets — — — 1.97 ARO Acceleration and other related costs — 0.02 — 0.03 Other 0.01 0.01 0.04 0.04 Income tax effect of non-GAAP adjustments(a) (0.41) (0.12) (0.80) (1.00)Adjusted net income per share - diluted $ 1.59 $ 1.75 $ 6.76 $ 6.23 Weighted-average common shares outstanding - diluted 72,451 70,092 71,651 70,239 (a)The income tax effect of the adjustments between GAAP net income and adjusted net income (non-GAAP) takes into account the tax treatment and related tax rate that apply to each adjustment in the applicable tax jurisdiction.Lantheus Holdings, Inc.
Reconciliation of GAAP to Non-GAAP Financial Measures (Continued)(in thousands, except per share data – unaudited) Three Months Ended December 31, Twelve Months Ended December 31, 2024 2023 2024 2023 Operating income $ 113,872 $ 137,486 $ 456,979 $ 364,642 Stock and incentive plan compensation 22,164 14,172 76,393 50,507 Amortization of acquired intangible assets 11,846 11,308 43,807 46,440 Campus consolidation costs 35 679 72 3,864 Contingent consideration fair value adjustments (1,294) 200 (2,699) (9,275)Non-recurring refinancing related fees — 5 — 221 Non-recurring fees 6,723 — 6,723 (2,734)Gain on sale of assets (2,161) — (8,415) — Strategic collaboration and license costs (8) — 66,213 — Acquisition-related costs 207 169 1,553 676 Impairment of long-lived assets — — — 138,050 ARO Acceleration and other related costs — 1,187 — 2,232 Other 447 531 2,720 2,725 Adjusted operating income $ 151,831 $ 165,737 $ 643,346 $ 597,348 Adjusted operating income, as a percentage of revenues 38.8% 46.8% 41.9% 46.1% Lantheus Holdings, Inc.
Worldwide revenue of $391.1 million and $1.53 billion for the fourth quarter and full year 2024Free cash flow was $141.4 million and $493.1 million for the fourth quarter and full year 2024GAAP fully diluted loss per share of $(0.17) and earnings per share of $4.36 for the fourth quarter and full year 2024Adjusted fully diluted earnings per share of $1.59 and $6.76 for the fourth quarter and full year 2024PYLARIFY exceeds $1 billion in net sales and becomes first ever blockbuster radiodiagnosticCompany announces a series of strategic asset and in-licensing deals that is expected to diversify its portfolio with early- to late-stage assets that position the company for continued growth in high potential marketsCompany provides full year 2025 revenue and adjusted diluted earnings per share guidance BEDFORD, Mass., Feb.26, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc.(Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today reported financial results for its fourth quarter and full year ended December 31, 2024.
The story "Lantheus Reports Fourth Quarter and Full Year 2024 Financial Performance" has 2707 words across 46 sentences, which will take approximately 12 - 23 minutes for the average person to read.
Which news outlet covered this story?
The story "Lantheus Reports Fourth Quarter and Full Year 2024 Financial Performance" was covered 15 hours ago by GlobeNewswire, a news publisher based in China.
How trustworthy is 'GlobeNewswire' news outlet?
GlobeNewswire is a fully independent (privately-owned) news outlet established in 1998 that covers mostly technology news.
The outlet is headquartered in China and publishes an average of 70 news stories per day.
It's most recent story was published 8 hours ago.
What do people currently think of this news story?
The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.
How do I report this news for inaccuracy?
You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.
